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of cellular abnormalities. The authors compared original cytotechnicians’ Papanicolaou (Pap) readings for which HPV sta-
tus was concealed with Pap rereads for which HPV status was revealed separately for 3 screening populations. METHODS:
Previously collected cervical Pap smears and clinical data were obtained from the Canadian Cervical Cancer Screening
Trial (study A), the Democratic Republic of Congo Community-Based Screening Study (study B), and the Brazilian Investi-
gation into Nutrition and Cervical Cancer Prevention (study C). Smears were reread with knowledge of HPV status for all
HPV-positive women as well as a sample of HPV-negative women. Diagnostic performance of Pap cytology was com-
pared between original readings and rereads. RESULTS: A total of 1767 Pap tests were reread. Among 915 rereads for
HPV-positive women, the contrast between “revealed” and “concealed” Pap readings demonstrated revisions from nega-
tive to positive results for 109 women (cutoff was atypical squamous cells of undetermined significance or worse) and 124
women (cutoff was low-grade squamous intraepithelial lesions [LSIL] or worse). For a disease threshold of cervical intrae-
pithelial neoplasia of grade 2 or worse, specificity significantly declined at the atypical squamous cells of undetermined
significance cutoff for studies A (86.6% to 75.3%) and C (42.5% to 15.5%), and at the LSIL cutoff for study C (61.9% to
37.6%). Sensitivity remained nearly unchanged between readings, except in study C, in which reread performance was
superior (91.3% vs 71.9% for the LSIL cutoff). CONCLUSIONS: A reduction in the diagnostic accuracy of Pap cytology was
observed when revealing patients’ cervical HPV status, possibly due to a heightened awareness of potential abnormalities,
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INTRODUCTION
In view of the well-established causal role for human pap-
illomavirus (HPV) in cervical neoplasia, cervical cancer
screening practices in most industrialized countries have
incorporated molecular testing for DNA of high-risk
HPV types (HR-HPV) as an adjunct to or as cotesting
with Papanicolaou (Pap) cytology. A third approach that
has gradually gained favor for women aged >25 or 30
years is to use HR-HPV testing as the primary screening
method, followed by Pap triage of women found to be
HR-HPV positive (HPV/Pap triage).1 This approach is
attractive in the sense that it takes advantage of the high
sensitivity of HPV testing as the primary screen while rely-
ing on the high specificity of Pap cytology to triage those
women found to be positive on first screen.2-5 HPV/Pap
triage has been assessed in various settings, including sev-
eral randomized controlled trials (RCTs) and simulation
studies.1-10 Another advantage of the HPV/Pap triage
approach is to reduce the number of tests performed com-
pared with Pap plus HPV cotesting. In practice, cytotech-
nicians would have a considerably reduced workload
(10-fold) but would spend more time scanning slides
because of the awareness that the Pap tests would have ori-
ginated from HR-HPV-positive women.
A true estimate of the efficacy of the HPV/Pap triage
algorithm before it is rolled out as standard practice would
theoretically require knowledge of a woman’s HPV infec-
tion status by the cytotechnician at the time of the Pap
reading. Cytotechnicians who are aware of a woman being
HPV positive may perform more meticulous assessments
of Pap tests, thus improving the accuracy of cytological
triage. Importantly, this could result in decreased false-
negative diagnoses, a more thorough evaluation of border-
line abnormalities, and a consequent increase in Pap sensi-
tivity as a triage test. Presumably, the longer time spent
reading a Pap test would also permit better scrutiny of
reactive atypias and thus it is conceivable that knowledge
of the HPV status may also impact favorably on the speci-
ficity of cytology as a triage tool.
Currently, to our knowledge there is scanty epide-
miologic evidence that cytology readings performed in
this context are more accurate than the current practice
(ie, Pap test reading without knowledge of the patient’s
HPV positivity status).11,12 The objectives of the current
study were to 1) assess the influence of revealed (rereads)
versus concealed (original readings) HPV DNA status on
cytotechnicians’ appraisal of cervical Pap tests and 2)
determine and compare the effectiveness of Pap cytology
as a triage test when cytotechnicians are made aware of the
woman’s cervical HPV status. We hypothesized that the
diagnostic performance of Pap cytology would improve if
HPV positivity were to be revealed.
MATERIALS AND METHODS
We set up the PEACHS (Pap Efficacy After Cervical
HPV Status) Study Consortium to bring together data
and specimens from 3 previously conducted epidemio-
logic studies to compare the performance of Pap rereads
with those from each original study. Cervical smear sam-
ples were obtained from the Newfoundland study site of
the Canadian Cervical Cancer Screening trial,2,13 the
Community-Based Screening Study from the Democratic
Republic of Congo,14,15 and the Brazilian Investigation
into Nutrition and Cervical Cancer Prevention.16-18 These
studies are referred to hereafter as studies A, B, and C,
respectively. Details regarding these parent studies and the
analysis sample for the current study are summarized in
Table 1.2-18 Written informed consent was obtained from
all participants.
Cytology and HR-HPV DNA Testing in Parent
Studies in PEACHS
Conventional Pap cytology was performed within studies
A and B. Study C used liquid-based cytology (LBC); col-
lected samples were released into liquid suspension using
the DNA-Cytoliq System (Digene Brazil, Sao Paulo, Bra-
zil). For the detection of HPV DNA in cervical samples,
the Digene Hybrid Capture 2 (hc2) HPV DNA assay
(Qiagen, Valencia, Calif) was used in studies A and B,
according to the manufacturer’s recommendations. A
polymerase chain reaction protocol (with MY09/11 pri-
mers) was used for HPVDNA testing in study C.16
Diagnostic Assessment in Parent Studies
Diagnoses were made via colposcopy-directed biopsies. In
study A, individuals underwent colposcopy for a positive
HPV test (hc2 test 1 pg/mL) or positive Pap test classi-
fied as atypical squamous cells of undetermined signifi-
cance (ASC-US) or worse.19 In study B, gynecologists
performed colposcopies on all participants, and biopsy
specimens (histopathological verification) were obtained
for women in whom lesional tissue was visualized during
colposcopy and for a 20% random sample of women with
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normal colposcopy findings. Participants in study C were
referred for colposcopy based on Pap test positivity at the
cutoff of ASC-US or worse.
Selection Criteria of Subsamples
The selection of subsamples was conditional on a wom-
an’s original cervical HPV status. All HPV-positive cases
and a sample (systematic sampling in study A and ran-
dom sampling in studies B and C) of HPV-negative cases
were selected. For studies A and B, HPV positivity was
defined as a positive result on hc2, whereas for study C it
was defined as positivity for 1 of 13 HPV genotypes
(types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and
68) that were detected in hc2. The selection of subsam-
ples was totally blind with respect to all other informa-
tion available for each subject, including disease status
and original cytology reading.
Cytology Reread Procedures
Cytological results were classified on the basis of The
Bethesda System,19 classifying Pap tests as negative for
intraepithelial lesions or malignancy (normal); ASC-US,
cannot exclude high-grade squamous intraepithelial
lesions; low-grade squamous intraepithelial lesion (LSIL);
or high-grade squamous intraepithelial lesion. Histopath-
ological ascertainment of the presence of cervical lesions
had been done in the parent studies based on the cervical
intraepithelial neoplasia (CIN) terminology with the asso-
ciated low (CIN1) or high (CIN2 or CIN3) grades. Stud-
ies B and C included cases of squamous cell carcinoma.
Original cytology readings and rereads for each of
the 3 studies were performed by trained cytotechnologists
who worked as regular employees in the accredited labora-
tories that served the 3 studies (Newfoundland, Canada
[study A]; Lyon, France [study B]; and Sao Paulo, Brazil
[study C]). Cytology training at all 3 sites was based on
local national standards that prevailed at the time of the
original studies and when rereads were negotiated. The
only exception was the cytopathology laboratory in Lyon,
France. France was not a study site but the absence of a
collaborating cytology laboratory in Kinshasa (study B)
led us to arrange a collaboration with the Lyon laboratory
TABLE 1. Characteristics of Parent Studies and Reread Subsamples: The PEACHS Study Consortium
Study A Study B Study C
Study characteristics
Name Canadian Cervical Cancer
Screening Trial2,13
Congo Community-Based
Screening Study14,15
Brazilian Investigation into
Nutrition and Cervical Cancer
Prevention16-18
Design Randomized controlled trial Cross-sectional split-sample
screening study
Hospital-based case-control
study
Location St. John’s (Newfoundland) and
Montreal (Quebec), Canada
Kinshasa, Democratic Republic of
Congo
Sao Paulo, Brazil
Recruitment period September 2002-February 2005 November 2003-April 2004 March 2003-May 2005
Recruitment population Women attending for regular
screening at 30 participating
preapproved family medicine
and gynecology primary clinics
Women invited to attend a
cervical cancer prevention pro-
gram at a local primary health
care center
Women attending for regular
screening at 1 of 3
participating public hospitals
Blinding of original test results
Cytology blinded to HPV Yes Yes Yes
HPV blinded to cytology Yes Yes Yes
Colposcopy blinded to cytology Yes Yes No
Colposcopy blinded to HPV Yes Yes Yes
Histology blinded to
colposcopy
Yes Yes Yes
Histology blinded to cytology Yes Yes No
Histology blinded to HPV Yes Yes Yes
Pap rereads
Sample selectiona All HPV1
Systematic sample of HPV2
All HPV1
Random sample of HPV2
All HPV1
Random sample of HPV2
Analysis Eastern Health Cytology
laboratory in St. John’s
Newfoundland, Canada
Groupement de Recherche
Cytologique in Lyon, France
Department of Pathology at
University of Sao Paulo
Time between readings 3 y 2 y 6 mo
Blinding Unblinded to HPV status
Blinded to original Pap reading,
colposcopy, and pathology
Unblinded to HPV status
Blinded to original Pap reading,
colposcopy, and pathology
Unblinded to HPV status
Blinded to original Pap reading,
colposcopy, and pathology
Abbreviations: 1, positive; 2, negative; HPV, human papillomavirus; Pap, Papanicolaou; PEACHS, Pap Efficacy After Cervical HPV Status.
a Smears were only obtained from the Newfoundland study site.
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for convenience. Pap tests were shipped directly to Lyon
by study personnel in Kinshasa. Cytotechnologist assign-
ment of the Pap test reading was outside of the study con-
trol but all readers were blinded to all clinical and
laboratory information except for the HPV status of the
sample.
Statistical Analysis
Cytology readings (original vs rereads) were analyzed
using 2 binary cutoffs for positivity; borderline result
(ASC-US) or worse and LSIL or worse. Agreement
between Pap readings (original vs rereads) was assessed
using the prevalence-adjusted, bias-adjusted kappa statis-
tic,20 which accounts for uneven distribution of data
across categories of cytology classifications. Binary agree-
ment was measured using the McNemar test. Estimates
of sensitivity and specificity were derived by classical 2-
by-2 contingency tables, and were also plotted on
receiver operating characteristic curves. Verification bias,
characterized by an overestimated sensitivity and an
underestimated specificity,21 was corrected for as recom-
mended.22 Verification bias is best explained by consider-
ing the finding that in typical clinical scenarios, the only
individuals to undergo the reference standard test for ver-
ification of disease are those who are screened as posi-
tive.23,24 This results in a systematic selection bias that, if
not accounted for, can lead to biased estimates of sensi-
tivity and specificity of the screening test being evaluated.
A method to account for this is to ascertain disease status
in a random subsample of disease-negative individuals
and apply correction formulae.22,25 Corrected sensitivity
and specificity estimates and associated 95% confidence
intervals (95% CIs) were calculated using the Stata
macro “Valides.”26 Analyses were performed using the
Stata statistical software package (Release 11.0; Stata-
Corp, College Station, TX).
TABLE 2. Study-Specific Disease Outcomes Defined by Histopathology According to HPV Status: The
PEACHS Study Consortium
NILM CIN1 CIN2 CIN3 ICC Unverified Totals
Study (Country) HPV Status No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Study A (Canada) HPV1 215 (82.4) 14 (5.4) 10 (3.8) 3 (1.1) 0 (0.0) 19 (7.3) 261 (100.0)
HPV2 16 (5.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 255 (94.1) 271 (100.0)
Study B (Congo) HPV1 46 (30.1) 12 (7.8) 5 (3.3) 16 (10.5) 0 (0.0) 74 (48.4)a 153 (100.0)
HPV2 83 (36.4) 3 (1.3) 0 (0.0) 0 (0.0) 1 (0.4) 141 (61.8) 228 (100.0)
Study C (Brazil)b HPV1 104 (20.8) 77 (15.4) 84 (16.8) 188 (37.5) 48 (9.6) 0 (0.0) 501 (100.0)
HPV2 278 (78.8) 37 (10.5) 19 (5.4) 14 (4.0) 5 (1.4) 0 (0.0) 353 (100.0)
Abbreviations: 1, positive; 2, negative; CIN, cervical intraepithelial neoplasia; HPV: human papillomavirus; ICC, invasive cervical cancer, includes squamous
cell carcinoma and adenocarcinoma; NILM, negative for intraepithelial lesions or malignancy; PEACHS, Pap Efficacy After Cervical HPV Status.
aWith respect to histopathology, all women underwent a colposcopy.
b Individuals in the control group were classified as NILM according to patient history.
Figure 1. Flow diagram for study-specific selection of Papani-
colaou (Pap) test reread samples in the PEACHS (Pap Effi-
cacy After Cervical HPV Status) Study Consortium. The
selection of smears for rereading was conditional on human
papillomavirus (HPV) status within each parent study. Origi-
nal cervical slides from parent studies were obtained for all
high-risk HPV-positive (HPV1) cases. For study A, Pap tests
were obtained only from the Newfoundland study site. A sub-
set of high-risk HPV-negative (HPV2) cases was selected
using systematic sampling for study A and random sampling
for studies B and C. Pap test rereads were performed by the
same cytotechnicians after the HPV status was revealed to
them. Both readings were performed with blinding for all
other results.
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RESULTS
In total, 1767 Pap tests were reread: 915 from HPV-
positive women (89% of original samples) and 852 from
HPV-negative women (12%) (Fig. 1). Exclusions were
made in the event of inconclusive Pap test results, slide
loss or breakage, or inadequacy of the tests at the time of
rereading (eg, decay of staining intensity). Disease out-
comes from each parent study according to the HPV sta-
tus of the samples are shown in Table 2. Outcome
verification in studies A and B was conditional on positive
screening test results, or if selected at random for disease
ascertainment. Of the 261 patients in study A with com-
pleted rereads, 242 (93%) were ascertained for disease.
For study B, 52% of patients were ascertained for disease
(79 of 153 available rereads). In study C, disease outcome
information was available for all individuals. Collectively,
among HPV-positive women, 103 cases of CIN1, 99
cases of CIN2, 207 cases of CIN3, and 48 cases of invasive
carcinoma were identified.
Table 3 shows the agreement between original
results and those after rereading the same Pap tests for
each parent study according to HPV status and cytological
threshold of positivity. Using the ASC-US cutoff, 85.8%
of 261 smears in study A were originally classified as nor-
mal, whereas 75.1% were considered normal at the time
of the reread. In study B, 62.7% of 153 tests were classi-
fied as normal at the time of the original readings and
57.5% as normal at the reread. In study C, 20.8% and
7.8%, respectively, of 501 Pap tests were classified as nor-
mal at the time of the original reading and at the reread.
For each study, significant disagreement between smear
readings were observed for HPV-positive women (as
shown in the columns 6 and -/1 in Table 3). In HPV-
negative women, cytotechnician readings tended to agree
between the original readings and rereads; there was per-
fect agreement (kappa of 1.0 at the ASC-US cutoff) in
study A and very strong agreement (kappa of 0.96 at the
ASC-US cutoff) in study B. In study C, agreement was
lower (kappa of 0.55 at the ASC-US cutoff) with many
discordant cases, mostly revisions from positive on origi-
nal readings to negative on rereads.
As shown in Table 4, specificity estimates were sig-
nificantly lower in rereads versus original readings in stud-
ies A and C at the outcome of CIN2 or worse. Specificity
at the ASC-US cutoff declined from 85.6% (95% CI,
80.4%-89.9%) to 73.4% (95% CI, 67.1%-79%) in study
A and from 42.5% (95% CI, 35.2%-50.1%) to 15.5%
(95% CI, 10.5%-21.6%) in study C. In addition, speci-
ficity significantly declined at the LSIL cutoff for study C,
from 61.9% (95% CI, 54.4%-69.0%) to 37.6% (95%
CI, 30.5%-45.1%). Sensitivity remained highly consist-
ent between original and reread Pap test results at the
ASC-US cutoff. However, at the LSIL cutoff, a significant
increase in sensitivity was found in study C (from 79.1%
[95% CI, 74.2%-83.4%] to 91.3% [95% CI, 87.6%-
94.1%]).
TABLE 3. Study-Specific Agreement Between Original Pap Cytology Readings and Rereads According to
HPV Status And Pap Cytology Threshold Of Positivity: The PEACHS Study Consortium
Study (Country) HPV Status Cutoff
Original Readings/Rereads
1/1 1/2 2/1 2/2 McNemar Test P Kappaa
Study A (Canada) HPV1 ASC-US 34 3 31 193 <.0001 0.74
LSIL 15 3 15 228 .0075 0.86
HPV2 ASC-US 0 0 0 271 NA 1.00
LSIL 0 0 0 271 NA 1.00
Study B (Congo) HPV1 ASC-US 57 0 8 88 .0078 0.90
LSIL 39 1 17 96 .0001 0.76
HPV2 ASC-US 7 3 1 217 .6250 0.96
LSIL 4 3 1 220 .6250 0.76
Study C (Brazil) HPV1 ASC-US 392 5 70 34 <.0001 0.70
LSIL 313 9 92 87 <.0001 0.60
HPV2 ASC-US 33 60 20 240 <.0001 0.55
LSIL 18 30 5 300 <.0001 0.80
Abbreviations: 1, positive; 2, negative; ASC-US, atypical squamous cells of undetermined significance; HPV, human papillomavirus; LSIL, low-grade squa-
mous intraepithelial lesion; NA, not applicable (no test statistic due to perfect agreement [100%]); Pap, Papanicolaou; PEACHS, Pap Efficacy After Cervical
HPV Status.
a Prevalence-adjusted, bias-adjusted Kappa statistic.
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Visual representation of sensitivity and specificity
estimates is shown in Figure 2, with directional arrows
plotting the changes from original readings to rereads at
the outcome of CIN2 or worse for the ASC-US and LSIL
cutoffs. Figure 2 clearly shows that, at the ASC-US cutoff,
rereads had decreased specificity compared with original
readings. Specificity estimates also declined in rereads at
the LSIL cutoff; however, gains in sensitivity were
observed in each parent study. Similar results were found
using CIN3 or worse as disease endpoint (data not
shown).
DISCUSSION
The current study addresses an important question of
whether a cytotechnician’s awareness that a Pap test to be
read came from a HR-HPV-positive woman will lead to
an improvement in the accuracy of the ensuing Pap
report, which is correlated with disease status. In practice,
this is the scenario that will prevail in settings that adopt
the HPV/Pap triage approach to cervical cancer screening
because Pap tests will only be read (or prepared from
LBC) if the initial screen with a validated HR-HPV test is
positive. We used previous molecular epidemiologic or
screening studies that had preserved Pap tests and data
regarding HPV positivity and cervical disease status. Our
hypothesis was that the extra time and attention devoted
by a reader who is aware that the patient harbors a cervical
HPV infection would have resulted in more meticulous
reading. The current study findings demonstrated that
revealing HPV positivity had a marked influence on the
cytotechnician’s grading of cervical Pap tests. There was a
tendency to overcall abnormalities in rereads of HPV-
positive women, which translated in more false-positives
findings at both the ASC-US and LSIL cutoffs with conse-
quent losses in specificity compared with the original
smear readings (blinded to HPV status). Conversely, in all
3 parent studies, there was a gain in sensitivity that was
pronounced when based at a threshold of LSIL to define a
positive smear.
The HPV/Pap triage serial screening algorithm is
best described as a testing-in-series design, specifically a
“test-if-positive” design; the second test (Pap cytology) is
performed based on positive results of the first test (HPV
testing). Therefore, derived Pap estimates are entirely con-
ditional on HPV positivity, and differ from uncondi-
tional, or stand-alone, Pap estimates.27 This prevents us
from comparing our sensitivity and specificity estimates
with previously derived estimates of Pap as a stand-alone
test, such as the often quoted 51% benchmark of Pap sen-
sitivity.28 Doing so could lead to erroneous inferences
regarding the performance of screening tests.
In a large-scale RCT performed in Finland, primary
HPV testing was evaluated in women as part of a mass
organized screening program.29 Women were random-
ized to either conventional Pap screening or HPV/Pap tri-
age. Pap triage was found to alleviate declines in
TABLE 4. Diagnostic 2-By-2 Tables: Sensitivity And Specificity Of Pap Cytology To Detect CIN21 In HPV1
Women According To Pap Cytology Cutoff: The PEACHS Study Consortium
Study (Country) Pap Cutoff Pap Readings
True-
Positive
No. (%)
False-
Positive
No. (%)
False-
Negative
No. (%)
True-
Negative
No. (%)
Sensitivity
Estimate (95% CI)
Specificity
Estimate (95% CI)
Study A (Canada) ASC-US Original 4 (1.7) 33 (13.6) 9 (3.7) 196 (81.0) 30.80 (9.1-61.4) 85.60 (80.4-89.9)
Reread 4 (1.7) 61 (25.2) 9 (3.7) 168 (69.4) 30.80 (9.1-61.4) 73.40 (67.1-79.0)
LSIL Original 2 (0.8) 16 (6.6) 11 (4.5) 213 (88.0) 15.40 (1.9-45.4) 93.00 (88.9-96.0)
Reread 4 (1.7) 26 (10.7) 9 (3.7) 203 (83.9) 30.80 (9.1-61.4) 88.60 (83.8-92.4)
Study B (Congo) ASC-US Original 18 (22.8) 18 (22.8) 3 (3.8) 40 (50.6) 85.70 (63.7-97.0) 69.00 (55.5-80.5)
Reread 18 (22.8) 22 (27.8) 3 (3.8) 36 (45.6) 85.70 (63.7-97.0) 62.10 (48.4-74.5)
LSIL Original 13 (16.5) 11 (13.9) 8 (10.1) 47 (59.5) 61.90 (38.4-81.9) 81.00 (68.6-90.1)
Reread 18 (22.8) 20 (25.3) 3 (3.8) 38 (48.1) 85.70 (63.7-97.0) 65.50 (51.9-77.5)
Study C (Brazil) ASC-US Original 293 (58.5) 104 (20.8) 27 (5.4) 77 (15.4) 91.60 (88.0-94.4) 42.50 (35.2-50.1)
Reread 309 (61.7) 153 (30.5) 11 (2.2) 28 (5.6) 96.60 (93.9-98.3) 15.50 (10.5-21.6)
LSIL Original 253 (50.5) 69 (13.8) 67 (13.4) 112 (22.4) 79.10 (74.2-83.4) 61.90 (54.4-69.0)
Reread 292 (58.3) 113 (22.6) 28 (5.6) 68 (13.6) 91.30 (87.6-94.1) 37.60 (30.5-45.1)
Abbreviations: 1, positive; 95% CI, 95% confidence interval; ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neo-
plasia; HPV: human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; Pap, Papanicolaou; PEACHS, Pap Efficacy After Cervical HPV Status.
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specificity compared with stand-alone HPV testing
(CIN2 or worse: specificity of 91.7% for HPV alone vs
98.9% for HPV/Pap triage). At follow-up, using HPV/
Pap triage resulted in significant gains in relative sensitiv-
ity.3 Given the absence of a direct comparison of blinded
estimates of sensitivity and specificity in the Finnish
study, we can only speculate regarding the potential level
of bias in specificity. However, the Finnish study was per-
formed within a structured organized screening program,
and therefore the quality control practices in place may
have counteracted the level of biases that we observed with
knowledge of HPV status.
Another RCT that evaluated the HPV/Pap triage
approach was performed in British Columbia, Canada
(HPV FOCAL study).30 In contrast to the Finnish trial,
LBC was used in the FOCAL trial. Initial (round 1)
results suggested that the use of HPV/Pap triage increases
specificity over high-risk HPV testing alone.31
More recently, a substudy of the New Technology
in Cervical Cancer RCT evaluated the influence of cyto-
technicians’ informed knowledge of HPV positivity.11
Comparing their uninformed Pap cytology readings with
their informed Pap cytology readings, a relative sensitivity
of 1.58 (95% CI, 1.22-2.01) at a cutoff of CIN2 or worse
was identified, which underscores the gain in Pap cytology
sensitivity that comes from revealing the HPV positivity
status. A gain in sensitivity with a minor loss in specificity
was also observed by Benoy et al in a study in Belgium.12
The low prevalence of disease in negative Pap tests is
a well-known contributing factor to the tendency toward
false-negative rates associated with Pap cytology.32 The
foremost rationale for HPV/Pap triage lies in the premise
that narrowing the caseload of Pap tests to only HPV-
positive women will alleviate the redundancy of reading
many negative Pap tests and enrich the caseload with tests
that are more likely to harbor precancerous lesions.1,32
Truly alleviating subjectivity may necessitate the
incorporation of newer technologies in the form of
improved preparation of Pap tests with enhanced read-
ability (ie, LBC rather than conventional cytology) or
alternatively through automated cytology technologies.
Although LBC is increasingly being incorporated into
screening programs, a certain level of speculation exists
with regard to the true benefit offered. As part of a cervical
screening RCT conducted in Italy, LBC (performed in
22,708 cases) did not appear to offer statistically signifi-
cant improvements in sensitivity over conventional cytol-
ogy (performed in 22,466 cases).33 In the current study,
LBC was used only in study C, which might explain in
part the relatively higher accuracy of sensitivity estimates
in that study. However, using an LBC medium for HPV
testing and the triage with Pap cytology of HPV-positive
women appears to improve the feasibility of an HPV/Pap
triage strategy by avoiding the need to obtain a new sam-
ple for a Pap cytology from HPV-positive women at a
follow-up visit.
The ability of a cytotechnician to reliably discern
true borderline abnormalities could presumably be
refined with more years of experience. The American
ASC-US and LSIL Triage Study found that, at the time of
reassessment of cervical smears and independent revision
by a cytopathology quality control team, the greatest dis-
cordance between readings was found in those originally
Figure 2. Summary receiver operating characteristic curve of
sensitivity and specificity estimates in human papillomavirus-
positive women in the PEACHS (Pap Efficacy After Cervical
HPV Status) Study Consortium. Study outcome was cervical
intraepithelial neoplasia of type 2 or worse. Drawn arrows
represent paths from original readings to rereads. A-o indi-
cates Canada study original readings; A-r, Canada study
rereads; B-o, Congo study original readings; B-r, Congo study
rereads; C-o, Brazil study original readings; C-r, Brazil study
rereads. Red arrows represent differences from original read-
ings to rereads at the cutoff of low-grade squamous intraepi-
thelial lesion (LSIL). Blue arrows represent differences from
original readings to rereads at the cutoff of atypical squa-
mous cells of undetermined significance (ASC-US). Estimates
shown for studies A and B were corrected for verification
bias.
HPV/Pap: Concealed Versus Revealed HPV/Richardson et al
Cancer Cytopathology December 2015 751
classified as ASC-US.34 Approximately 39% of cytologi-
cal tests deemed as ASC-US at the time of the original
reading were revised to negative on quality control review,
with moderate agreement observed between cytological
readings (kappa of 0.46). In contrast, the declines in
agreement in the current study were driven down by
changes from negative on original readings to ASC-US on
rereads. One may speculate whether the loss in specificity
due to upgrades to ASC-US from negative could be coun-
teracted by a well-organized quality control program. The
current study differed in that both of our readings were
performed by cytotechnicians, with no formal quality
review performed other than the laboratories’ accredita-
tion of parent studies, and the fact that we considered a
group entirely composed of HPV-positive women com-
pared with a 37%HPV-positivity rate in the ASC-US and
LSIL Triage Study trial.34 Had our positive reread reports
been verified via a cytopathologist’s quality review, we
might not have observed such a decline in specificity.
Conversely, cytotechnicians may have been more percep-
tive of minor HPV-associated cellular changes and
decided to call the Pap tests positive despite the fact that
such changes were not important enough to translate into
histopathologically recognizable lesions.
We assessed the influence of HPV-revealed rereads
in random samples of HPV-negative patients to give us a
better understanding of reproducibility in a situation in
which little change would be expected, as well as to assess
for differences between readings that may be representative
of personnel changes and a potential decline in test quality
over time. Evidently, we found agreement to be much
higher in HPV-negative compared with HPV-positive
individuals, given the high percentages of negative Pap
tests, which is expected for HPV-negative women. Knowl-
edge that women are negative for HPV infection may pro-
vide reassurance to cytotechnicians in reaffirming what are
more easily discerned as negative results.
A strength of the current study was the opportunity
to compare findings across 3 vastly different study set-
tings, which reflect the reality of 3 markedly different
countries with respect to the incidence of cervical cancer:
low (Canada), intermediate (Brazil), and high (Congo).
Similar trends were observed across studies despite sample
size limitations, substantial heterogeneity across studies,
and a relatively small sample for disease outcomes. Greater
precision and accuracy was permitted in study C, in which
47% of patients were HPV-positive women with high-
grade CIN3 or worse. The findings of the current study
possibly reflect the various levels of influence that knowl-
edge of HPV status could have within different screening
settings. Of greatest clinical interest was our observed
diagnostic performance of a Pap test at the LSIL thresh-
old; specificity estimates were not found to be substan-
tially affected on rereading but there were gains in
sensitivity. This finding was expected given the subjectiv-
ity associated with the ASC-US “borderline” category.
The findings of the current study are provocative
and counterintuitive. We failed to confirm our original
hypothesis of across-the-board gains in performance that
we expected to occur with an artificially high disease prev-
alence (ie, the tray of Pap tests from HPV-positive
women) and reduced workload (ie, <10% of all Pap
tests). We expected that awareness of HPV positivity
would have improved the accuracy of readings because
cytotechnicians would be compelled to meticulously focus
on abnormalities that would have otherwise gone unno-
ticed if the Pap test reading workload were not enriched
(ie, had a low prevalence of lesions). Actually, heightened
attention appears to have led to more false-positive results,
which adversely affected specificity with the consequence
of more women been referred for colposcopy.
The current study findings underscore the impor-
tance of maintaining meticulous quality control practices
for cytology, even when it is serving as a triage test subse-
quent to primary HPV testing. Our observation of better
preserved estimates at the higher LSIL threshold suggests
that off-setting the loss in specificity may be achieved
through the use of LSIL as a cutoff for Pap positivity
within the context of diagnostic triage. Third-party review
by cytopathologist appraisal may also counter the tend-
ency toward overcalls observed due to revealed HPV
positivity.
Because cohorts of vaccinated women will reach
screening age over the next few decades, declines in onco-
genic HPV infections that vaccines protect against could
be anticipated. Although our data sets do not include vac-
cinated women, the current study provided a unique set-
ting in which to assess the diagnostic triage value of Pap
cytology for HPV-positive women. Avoidance of subjec-
tivity may ultimately necessitate the consideration of
molecular markers, including HPV genotyping, to aug-
ment the value of cytology.
In practice, the HPV/Pap triage approach has been
successfully implemented in some real-world settings,
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with gains in efficiency noted in the detection of high-
grade precancerous lesions and cancer and reduced wait
times for Pap test processing and scheduling of colposcop-
ies.35 These findings indicate that in the new strategy of
HPV/Pap triage cytology, quality control will have to
incorporate safeguards to protect against a tendency to
overcall cytological grades. p16 staining and other
markers may provide the same benefit.36 However, after
20 to 30 years, nearly all women entering screening age
will have been vaccinated and lesion prevalence will have
been reduced to levels that will be so low as to affect the
overall efficiency of any cervical cancer screening pro-
gram, irrespective of technology. A reassessment of cervi-
cal cancer screening in all its dimensions will have to be
made with due attention to the balance of risks and bene-
fits that will prevail in an era of very low risk for cervical
cancer and its precursors.1,32
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